1. Home
  2. CBAT vs PRLD Comparison

CBAT vs PRLD Comparison

Compare CBAT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBAT
  • PRLD
  • Stock Information
  • Founded
  • CBAT 1999
  • PRLD 2016
  • Country
  • CBAT China
  • PRLD United States
  • Employees
  • CBAT N/A
  • PRLD N/A
  • Industry
  • CBAT Industrial Machinery/Components
  • PRLD Medicinal Chemicals and Botanical Products
  • Sector
  • CBAT Miscellaneous
  • PRLD Health Care
  • Exchange
  • CBAT Nasdaq
  • PRLD Nasdaq
  • Market Cap
  • CBAT 71.6M
  • PRLD 73.7M
  • IPO Year
  • CBAT N/A
  • PRLD 2020
  • Fundamental
  • Price
  • CBAT $0.76
  • PRLD $0.79
  • Analyst Decision
  • CBAT
  • PRLD Strong Buy
  • Analyst Count
  • CBAT 0
  • PRLD 2
  • Target Price
  • CBAT N/A
  • PRLD $4.50
  • AVG Volume (30 Days)
  • CBAT 156.1K
  • PRLD 254.6K
  • Earning Date
  • CBAT 03-17-2025
  • PRLD 05-06-2025
  • Dividend Yield
  • CBAT N/A
  • PRLD N/A
  • EPS Growth
  • CBAT N/A
  • PRLD N/A
  • EPS
  • CBAT 0.13
  • PRLD N/A
  • Revenue
  • CBAT $176,614,609.00
  • PRLD $7,000,000.00
  • Revenue This Year
  • CBAT $28.79
  • PRLD N/A
  • Revenue Next Year
  • CBAT $36.77
  • PRLD N/A
  • P/E Ratio
  • CBAT $5.92
  • PRLD N/A
  • Revenue Growth
  • CBAT N/A
  • PRLD N/A
  • 52 Week Low
  • CBAT $0.71
  • PRLD $0.63
  • 52 Week High
  • CBAT $2.08
  • PRLD $6.80
  • Technical
  • Relative Strength Index (RSI)
  • CBAT 33.80
  • PRLD 51.77
  • Support Level
  • CBAT $0.71
  • PRLD $0.71
  • Resistance Level
  • CBAT $0.90
  • PRLD $0.76
  • Average True Range (ATR)
  • CBAT 0.05
  • PRLD 0.07
  • MACD
  • CBAT -0.01
  • PRLD 0.02
  • Stochastic Oscillator
  • CBAT 26.42
  • PRLD 65.50

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Share on Social Networks: